Central Sympatholysis as a Novel Countermeasure for Cocaine-Induced Sympathetic Activation and Vasoconstriction in Humans

Journal of the American College of Cardiology

Volumn 50, Issue 7, 2007, Pages 626-633

  Menon, Dileep V ^a   Wang, Zhongyun ^a   Fadel, Paul J ^a   Arbique, Debbie ^a   Leonard, David ^a   Li, Jia Ling ^a   Victor, Ronald G ^a   Vongpatanasin, Wanpen ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; COCAINE; DEXMEDETOMIDINE;

ADRENERGIC STIMULATION; ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG TARGETING; FEMALE; GENE MUTATION; GENOTYPE; HEART RATE; HUMAN; LASER FLOWMETER; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; NEGRO; NORADRENALIN RELEASE; NORMAL HUMAN; PRIORITY JOURNAL; SKIN BLOOD FLOW; SYMPATHETIC BLOCKING; SYMPATHETIC TONE; VASCULAR RESISTANCE; VASOCONSTRICTION; VASOMOTOR REFLEX;

ADRENERGIC ALPHA-AGONISTS; ADULT; COCAINE; DEXMEDETOMIDINE; FEMALE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, ADRENERGIC, ALPHA-2; SKIN; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS; VASOMOTOR SYSTEM;

EID: 34547561841     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.03.060     Document Type: Article

References (35)

1. Substance Abuse and Mental Health Services Administration. 2003 National Survey on Drug Use & Health: Detailed Tables (2003), Office of Applied Studies, U.S. Department of Health and Human Services, Rockville, MD
2. Lange R.A., and Hillis L.D. Cardiovascular complications of cocaine use. N Engl J Med 345 (2001) 351-358
3. Vongpatanasin W., Mansour Y., Chavoshan B., Arbique D., and Victor G.R. Cocaine stimulates the human cardiovascular system via a central mechanism of action. Circulation 100 (1999) 497-502
4. Tuncel M., Wang Z., Arbique D., Fadel P.J., Victor R.G., and Vongpatanasin W. Mechanism of the blood pressure-raising effect of cocaine in humans. Circulation 105 (2002) 1054-1059
5. Mo W., Arruda J.A., Dunea G., and Singh A.K. Cocaine-induced hypertension: Role of the peripheral sympathetic system. Pharmacol Res 40 (1999) 139-145
6. Coursin D.B., Coursin D.B., and Maccioli G.A. Dexmedetomidine. Curr Opin Crit Care 7 (2001) 221-226
7. Masuki S., Dinenno F.A., Joyner M.J., and Eisenach J.H. Selective alpha2-adrenergic properties of dexmedetomidine over clonidine in the human forearm. J Appl Physiol 99 (2005) 587-592
8. Tanskanen P.E., Kytta J.V., Randell T.T., and Aantaa R.E. Dexmedetomidine as an anaesthetic adjuvant in patients undergoing intracranial tumour surgery: a double-blind, randomized and placebo-controlled study. Br J Anaesth 97 (2006) 658-665
9. Ozkose Z., Demir F.S., Pampal K., and Yardim S. Hemodynamic and anesthetic advantages of dexmedetomidine, an alpha2-agonist, for surgery in prone position. Tohoku J Exp Med 210 (2006) 153-160
10. Kersten J.R., Pagel P.S., Hettrick D.A., and Warltier D.C. Dexmedetomidine partially attenuates the sympathetically mediated systemic and coronary hemodynamic effects of cocaine. Anesth Analg 80 (1995) 114-121
11. Small K.M., Wagoner L.E., Levin A.M., Kardia S.L., and Liggett S.B. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347 (2002) 1135-1142
12. American Heart Association. Heart and stroke statistical-2006 update. Circulation 113 (2006) e85-e151
13. Ebert T.J., Hall J.E., Barney J.A., Uhrich T.D., and Colinco M.D. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology 93 (2000) 382-394
14. Valbo A.B., Hagbarth K.-E., Torebjork H.E., and Wallin B.G. Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves. Physiol Rev 59 (1979) 919-957
15. Li J.L., Canham R.M., Vongpatanasin W., Leonard D., Auchus R.J., and Victor R.G. Do allelic variants in alpha2A and alpha2C adrenergic receptors predispose to hypertension in blacks?. Hypertension 47 (2006) 1140-1146
16. Victor R.G., Haley R.W., Willett D.L., et al. The Dallas Heart Study: a population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. Am J Cardiol 93 (2004) 1473-1480
17. Johns M.E., and Henderson R.L. Cocaine use by the otolaryngologist: a survey. Trans Am Acad Ophthal Otolaryngol 84 (1977) 969-973
18. Vissing S.F., Scherrer U., and Victor R.G. Increase of sympathetic discharge to skeletal muscle but not to skin during mild lower body negative pressure in humans. J Physiol 481 (1994) 233-241
19. Wilson T.E., Cui J., and Crandall C.G. Absence of arterial baroreflex modulation of skin sympathetic activity and sweat rate during whole-body heating in humans. J Physiol 536 (2001) 615-623
20. Small K.M., Forbes S.L., Rahman F.F., Bridges K.M., and Liggett S.B. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha 2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 275 (2000) 23059-23064
21. Neumeister A., Charney D.S., Belfer I., et al. Sympathoneural and adrenomedullary functional effects of alpha2C-adrenoreceptor gene polymorphism in healthy humans. Pharmacogenet Genomics 15 (2005) 143-149
22. Makaritsis K.P., Handy D.E., Johns C., Kobilka B., Gavras I., and Gavras H. Role of the alpha2B-adrenergic receptor in the development of salt-induced hypertension. Hypertension 33 (1999) 14-17
23. Makaritsis K.P., Johns C., Gavras I., et al. Sympathoinhibitory function of the alpha(2A)-adrenergic receptor subtype. Hypertension 34 (1999) 403-407
24. Brede M., Philipp M., Knaus A., Muthig V., and Hein L. Alpha2-adrenergic receptor subtypes-novel functions uncovered in gene-targeted mouse models. Biol Cell 96 (2004) 343-348
25. Kaye D.M., Smirk B., Finch S., Williams C., and Esler M.D. Interaction between cardiac sympathetic drive and heart rate in heart failure: modulation by adrenergic receptor genotype. J Am Coll Cardiol 44 (2004) 2008-2015
26. Maccioli G.A. Dexmedetomidine to facilitate drug withdrawal. Anesthesiology 98 (2003) 575-577
27. Baddigam K., Russo P., Russo J., and Tobias J.D. Dexmedetomidine in the treatment of withdrawal syndromes in cardiothoracic surgery patients. J Intensive Care Med 20 (2005) 118-123
28. Wijeysundera D.N., Naik J.S., and Beattie W.S. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. Am J Med 114 (2003) 742-752
29. American Heart Association. 2005 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care: Part 10.2: toxicology in ECC. Circulation 112 (2005) IV126-IV132
30. Brogan III W.C., Lange R.A., Kim A.S., Moliterno D.J., and Hillis L.D. Alleviation of cocaine-induced coronary vasoconstriction by nitroglycerin. J Am Coll Cardiol 18 (1991) 581-586
31. Baumann B.M., Perrone J., Hornig S.E., Shofer F.S., and Hollander J.E. Randomized, double-blind, placebo-controlled trial of diazepam, nitroglycerin, or both for treatment of patients with potential cocaine-associated acute coronary syndromes. Acad Emerg Med 7 (2000) 878-885
32. Honderick T., Williams D., Seaberg D., and Wears R. A prospective, randomized, controlled trial of benzodiazepines and nitroglycerine or nitroglycerine alone in the treatment of cocaine-associated acute coronary syndromes. Am J Emerg Med 21 (2003) 39-42
33. Saland K.E., Hillis L.D., Lange R.A., and Cigarroa J.E. Influence of morphine sulfate on cocaine-induced coronary vasoconstriction. Am J Cardiol 90 (2002) 810-811
34. Boehrer J.D., Moliterno D.J., Willard J.E., Hillis L.D., and Lange R.A. Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. Am J Med 94 (1993) 608-610
35. Negus B.H., Willard J.E., Hillis L.D., et al. Alleviation of cocaine-induced coronary vasoconstriction with intravenous verapamil. Am J Cardiol 73 (1994) 510-513